M
Michael A. Dorato
Researcher at Eli Lilly and Company
Publications - 12
Citations - 2600
Michael A. Dorato is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Toxicology testing & Safety pharmacology. The author has an hindex of 7, co-authored 12 publications receiving 2333 citations.
Papers
More filters
Journal ArticleDOI
Concordance of the toxicity of pharmaceuticals in humans and in animals.
Harry Olson,Graham Betton,Denise Robinson,Karluss Thomas,A.M. Monro,Gerald Kolaja,Patrick D. Lilly,James E. Sanders,Glenn Sipes,William Bracken,Michael A. Dorato,Koen Van Deun,Peter Smith,Bruce Berger,Allen H. Heller +14 more
TL;DR: The survey results support the value of in vivo toxicology studies to predict for many significant HTs associated with pharmaceuticals and have helped to identify HT categories that may benefit from improved methods.
Journal ArticleDOI
Biological stress response terminology: Integrating the concepts of adaptive response and preconditioning stress within a hormetic dose-response framework
Edward J. Calabrese,Kenneth Bachmann,A. John Bailer,P. Michael Bolger,Jonathan Borak,Lu Cai,Nina Cedergreen,M. George Cherian,Chuang Chin Chiueh,Thomas W. Clarkson,Ralph R. Cook,David M. Diamond,David J. Doolittle,Michael A. Dorato,Stephen O. Duke,Ludwig E. Feinendegen,Donald E. Gardner,Ronald W. Hart,Kenneth L. Hastings,A. Wallace Hayes,George R. Hoffmann,John A. Ives,Zbigniew Jaworowski,Thomas E. Johnson,Wayne B. Jonas,Norbert E. Kaminski,John G. Keller,James E. Klaunig,Thomas B. Knudsen,Walter J. Kozumbo,Teresa Lettieri,Shu Zheng Liu,Andre Maisseu,Kenneth I. Maynard,Edward J. Masoro,Roger O. McClellan,Harihara M. Mehendale,Carmel Mothersill,David B. Newlin,Herbert N. Nigg,Frederick W. Oehme,Robert F. Phalen,Martin A. Philbert,Suresh I. S. Rattan,Jim E. Riviere,Joseph Rodricks,Robert M. Sapolsky,Bobby R. Scott,Colin Seymour,David A. Sinclair,Joan Smith-Sonneborn,Elizabeth T. Snow,Linda P. Spear,Donald E. Stevenson,Yolene Thomas,Maurice Tubiana,Gary M. Williams,Mark P. Mattson +57 more
TL;DR: This article offers a set of recommendations that scientists believe can achieve greater conceptual harmony in dose-response terminology, as well as better understanding and communication across the broad spectrum of biological disciplines.
Journal ArticleDOI
The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)
TL;DR: The issues and application of a functional definition of the NOAEL in toxicology evaluations are discussed and a common definition, "the highest experimental point that is without adverse effect," is served well in general discussions.
Journal ArticleDOI
Inhalation exposure technology, dosimetry, and regulatory issues.
TL;DR: Important aspects of study design, such as high level particulate exposures resulting in large lung burdens, slowed pulmonary clearance rates, and nonspecific toxicity are considered, along with practical issues of comparative dosimetry.
Journal ArticleDOI
Toxicology testing in drug discovery and development.
TL;DR: The typical toxicology profile consists of safety pharmacology, genetic toxicology, acute and subchronic Toxicology, absorption, distribution, metabolism, and excretion studies, reproductive and developmental toxicity, and an evaluation of carcinogenic potential.